A Study of Renal Autologous Cell Therapy (REACT) in Type 2 Diabetics With Chronic Kidney Disease

Prior treatment

• 1\. The subject is currently receiving renal dialysis.

Other illness

• The subject has a history of type 1 diabetes mellitus.
• The subject has a history of renal transplantation.
• The subject has uncontrolled diabetes (defined as metabolically unstable by the Investigator).

Lab values

• The subject has a serum Hemoglobin A1c (HbA1c) level greater than 10% at the Screening Visit.
• The subject has hemoglobin levels less than 9 g/dL prior to each Renal Autologous Cell Therapy (REACT) injection.

• The subject is male or female, 30 to 80 years of age on the date of informed consent.
• The subject has an established diagnosis of Type 2 Diabetes Mellitus.
• The subject has an established diagnosis of diabetic nephropathy as the underlying cause of renal disease.
• The subject has an established diagnosis of Chronic Kidney Disease not requiring renal dialysis, defined as having an Estimated Glomerular Filtration Rate (eGFR) between 20 and 50 mL/min/1.73m².
• The subject has blood pressure less than 150/90 at the Screening Visit.
• The subject has stable blood pressure and is maintained on a stable anti-hypertensive medication regimen.
• A minimum of 2 measurements of Estimated Glomerular Filtration Rate (eGFR) or serum creatine ratio (sCr) should be obtained at least 3 months apart prior to the Screening Visit or within the previous 18 months to define the rate of progression of Chronic Kidney Disease (CKD).
• The subject is willing and able to provide signed informed consent.
• The subject was enrolled into Part 1 of the study and received at least one Renal Autologous Cell Therapy (REACT) injection.